SCHEMBL315182

SCHEMBL315182

CC1CNc2cc(Cl)ccc2-n2c(-c3cccc(Cl)c3)nnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.43
HSD11B1 P28845 1/20 0.37
BRD4 O60885 6/20 0.36
ALDH1A1 P00352 2/20 0.36
AVPR1A P37288 1/20 0.36
HIF1A Q16665 1/20 0.35
LMNA P02545 1/20 0.35
GABRA1 P14867 1/20 0.35
HPGD P15428 1/20 0.35
CNR1 P21554 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
OPRK1 P41145 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
LRRK2 Q5S007 1/20 0.35
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL315184 1.00 TP53 (0.43) TP53HSD11B1BRD4ALDH1A1AVPR1A
SCHEMBL315183 1.00 TP53 (0.43) TP53HSD11B1BRD4ALDH1A1AVPR1A
SCHEMBL314491 0.94 ALDH1A1 (0.41) TP53BRD4ALDH1A1AVPR1ALMNA
SCHEMBL314493 0.94 ALDH1A1 (0.41) TP53BRD4ALDH1A1AVPR1ALMNA
SCHEMBL314492 0.94 ALDH1A1 (0.41) TP53BRD4ALDH1A1AVPR1ALMNA
SCHEMBL314677 0.92 HSD11B1 (0.41) TP53HSD11B1BRD4AVPR1ALMNA
SCHEMBL314678 0.92 HSD11B1 (0.41) TP53HSD11B1BRD4AVPR1ALMNA
SCHEMBL314679 0.92 HSD11B1 (0.41) TP53HSD11B1BRD4AVPR1ALMNA
SCHEMBL313997 0.91 HSD11B1 (0.39) TP53HSD11B1BRD4ALDH1A1AVPR1A
SCHEMBL314215 0.91 HSD11B1 (0.39) TP53HSD11B1BRD4ALDH1A1AVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 TP53 293/4885HSD11B1 1123/4885BRD4 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.